

## DATA SUPPLEMENT

### Clinical details of the 11 pairs of affected and non-affected co-twins

Duration of medication was estimated from hospital records. None of the co-twins without manifest schizophrenia had bipolar disorder. Schizotypal personality disorders were present in several co-twins, in line with expectations for this sample. A sample of 23 twin pairs (out of the original sample of 335 pairs) were approached and asked to take part in the study. Ten pairs refused, for example because they would have had to travel a long distance to the laboratory or because they had recently taken part in other measurements. Out of the 13 pairs who agreed, 2 failed to attend.

Twin-pair	Age (years)	Gender	Zygosity	Medication		Diagnosis (DSM–III–R code)
				Dosage (mg CPZeq)	Duration (years)	
I	54	M	DZ	0	28	Undifferentiated type (295.9C)
I	54	M	DZ			
2	50	M	DZ	20	25	Schizoaffective disorder (295.7A)
2	50	M	DZ			
3	49	M	DZ	30	25	Undifferentiated type (295.9C)
3	49	M	DZ			
4	53	M	MZ	50	20	Paranoid type (295.3C)
4	53	M	MZ			
5	48	F	MZ	200	20	Paranoid type (295.3C)
5	48	F	MZ			
6	56	F	DZ	10	35	Catatonic type (295.2C)
6	56	F	DZ			
7	61	M	MZ	35	25	Paranoid type (295.3C)
7	61	M	MZ			
8	52	F	DZ	300	20	Paranoid type (295.3F)
8	52	F	DZ			
9	59	M	DZ	500	35	Residual type (295.6C)
9	59	M	DZ			
10	58	M	MZ	200	25	Undifferentiated type (295.9C)
10	58	M	MZ			
11	64	M	MZ	380	25	Paranoid type (295.3E)
11	64	M	MZ			

CPZeq, Chlorpromazine equivalent; DZ, dizygotic; F, female; M, male; MZ, monozygotic.